Table 3

Prevalence of various retinopathy complications in the former DCCT INT and CONV at DCCT closeout, EDIC year 10, and EDIC years 15–18 among 1,214 patients evaluated for retinopathy or CSME during EDIC years 15–18

DCCT closeout (n = 1,214)EDIC year 10 (n = 1,133)EDIC years 15–18 (n = 1,214)
Retinopathy complicationsINT*CONVOdds reduction (%, CI)PINTCONVAdjusted odds reduction (%, CI)§PINTCONVAdjusted odds reduction (%, CI)§P
 ≥3 step progression from DCCT baseline9.231.578 (69, 84)<0.000134.360.660 (49, 69)<0.000141.158.741 (25, 54)<0.0001
 SNPDR or worse (SNPDR+) (%)2.28.376 (55, 87)<0.00018.825.862 (43, 75)<0.000115.931.542 (20, 58)0.001
 PDR or worse (PDR+) (%)2.07.073 (48, 86)<0.00018.625.463 (43, 75)<0.000115.731.543 (21, 59)0.001
 CSME (%)3.86.846 (7, 68)0.0249.420.444 (17, 63)0.00417.026.023 (−4, 44)0.09
 Photocoagulation therapy (%)3.37.759 (30, 76)0.00079.325.458 (37, 72)<0.000117.230.933 (9, 51)0.010
  • * Each subject was assessed once every 4 years during years 15–18 of EDIC timed to the year of entry into the DCCT. All subjects (consenting) were assessed at years 4 and 10.

  • Owing to staggered retinal assessments, patients could have completed an EDIC retinal examination that did not show progression, but later received treatment due to progression during the interim. Accordingly, such patients with scatter photocoagulation after the last retinal examination were counted as worsening for retinopathy (SNPDR or PDR); those with focal photocoagulation or on anti-VEGF were counted as worsening for macular edema (CSME). The n for CSME does not include patients who received pan-retinal photocoagulation for retinopathy.

  • The odds reduction is for intensive therapy as compared with conventional therapy. The percent reduction in the odds for the INT versus CONV was computed as (1 − odds ratio) × 100.

  • § Adjusted odds reduction was computed after stratification by the level of retinopathy at the end of the DCCT as shown in Table 1. Since this analysis is limited to the 1,214 patients with retinopathy evaluated at years 15–18, the risk reduction at EDIC year 10 is slightly different from that previously published (8).

  • Prior photocoagulation therapy is based on fundus photography grading and/or patient reporting. Photocoagulation includes pan-retinal laser for retinopathy or focal laser or use of anti-VEGF for CSME.